The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted approval of Xtandi in the treatment of men with castrate resistant prostate cancer that has progressed after the use of chemotherapy. It has already been approved for use in the United States. Xtandi (aka Enzalutamide and MDV3100) is a strong androgen [...]
Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]
The committee to start the early access clinical trials for drugs and treatments for men with advanced prostate cancer has been very hard at work. Based on the leadership and tenacity of Jan Manarite of the Prostate Cancer Research Institute (PCRI) we have managed to encourage, beg and cajole a number of pharmaceutical (pharma) companies [...]
I don’t understand why if I have hormone resistant advanced prostate cancer why the new drugs, Zytiga and Xtandi work. These drugs are still hormone therapies, is my prostate cancer hormone resistant? I recently received an email asking me this question and I thought it might be a question many people have, so I am [...]
In 1999 there was a new company started, InSightec, when GE Healthcare and Elbit Medical imaging joined their technologies to develop and manufacture non-invasive magnetic resonance (MRI) guided focused ultrasound technologies. The company has been in the process of developing a system that combines MRIs with ultrasound to non-surgically destroy fibroids and tumors. The company [...]